Targeting MUC1-C inhibits the AKT-S6K1-elF4A pathway regulating TIGAR translation in colorectal cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Targeting MUC1-C inhibits the AKT-S6K1-elF4A pathway regulating TIGAR translation in colorectal cancer

Published:2017-02-02 Issue:1 Volume:16 Page:
ISSN:1476-4598
Container-title:Molecular Cancer
language:en
Short-container-title:Mol Cancer

Author:

Ahmad Rehan,Alam Maroof,Hasegawa Masanori,Uchida Yasumitsu,Al-Obaid Omar,Kharbanda Surender,Kufe Donald

Funder

National Institutes of Health

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Molecular Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12943-017-0608-9.pdf

Reference44 articles.

1. Hagan S, Orr M, Doyle B. targeted therapies in colorectal cancer-an integrative view by PPPM. EPMA J. 2013;4(3):1–16.

2. Morin PJ, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 1997;275:1787–90.

3. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330–7.

4. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005;434:843–50.

5. Humphries A, Wright NA. Colonic crypt organization and tumorigenesis. Nat Rev Cancer. 2008;8:415–24.

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High-throughput neural stem cell-based drug screening identifies S6K1 inhibition as a selective vulnerability in sonic hedgehog-medulloblastoma;Neuro-Oncology;2024-06-11

2. Unraveling the role of C1GALT1 in abnormal glycosylation and colorectal cancer progression;Frontiers in Oncology;2024-04-18

3. High-throughput neural stem cell-based drug screening identifies S6K1 inhibition as a selective vulnerability in SHH-medulloblastoma;2024-02-02

4. Immune landscape of hepatocellular carcinoma: The central role of TP53-inducible glycolysis and apoptosis regulator;Open Medicine;2024-01-01

5. Cancer Drug Resistance and Metabolic Reprogramming;Drug Resistance in Cancer: Mechanisms and Strategies;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3